Biodesix Inc. Reports Q4 and FY2025 Financial Results

What Happened

• Biodesix, Inc. (BDSX) filed an 8‑K on February 26, 2026 (Item 2.02) announcing the company's financial and operating results for the fourth quarter and the fiscal year ended December 31, 2025.
• The company furnished a press release dated February 26, 2026 as Exhibit 99.1, which contains the detailed results and is incorporated by reference into the 8‑K.

Key Details

• Filing date: February 26, 2026 (Form 8‑K).
• Reporting period: Fourth quarter and fiscal year ended December 31, 2025.
• Exhibit: Press release provided as Exhibit 99.1 to the 8‑K.
• Signature: Report signed by Robin Harper Cowie, Chief Financial Officer, on behalf of Biodesix.

Why It Matters

• This 8‑K signals that Biodesix has released its latest quarterly and annual earnings and operating results; those numbers and commentary are contained in the attached press release (Exhibit 99.1).
• Investors should review the press release for revenue, earnings (or loss), cash position, guidance (if provided), and management commentary to assess the company’s recent performance and near‑term outlook.
• The filing itself is a prompt to check the full press release and any subsequent investor materials (earnings call slides, 10‑K) for the specific financial metrics and potential market impact.